Reported about 14 hours ago
Regeneron has agreed to buy DNA-testing company 23andMe for $256 million after it declared bankruptcy, a significant drop from its $6 billion valuation in 2021. The acquisition will see 23andMe continue its operations under Regeneron, utilizing its database of 15 million DNA samples to aid in drug discovery, while ensuring compliance with privacy policies. Despite past struggles to profit, the deal aims to enhance genetic research and personal health initiatives.
Source: YAHOO